Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 576 - 600 of 11929 in total
Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections. Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved...
Approved
Matched Iupac: … 5R)-3-methyl-4,4,7-trioxo-3-[(1H-1,2,3-triazol-1-yl)methyl]-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2- …
Matched Salts cas: … 89785-84-2
Matched Mixtures name: … TAZOJECT 2 G/ 0,25G IV ENJEKSIYONLUK LIYOFILIZE TOZ, 25 ADET ... TAZOJECT 2 G/ 0,25G IV ENJEKSIYONLUK LIYOFILIZE TOZ, 1 ADET ... Piperacillin/Tazobactam Ibigen 2 g/0,25 g Pulver zur Herstellung einer Infusionslösung …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Approved
Investigational
Matched Iupac: … (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid …
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe...
Approved
Illicit
Investigational
Withdrawn
Matched Iupac: … (2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl propanoate …
Matched Mixtures name: … Darvocet-N 50
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.
Approved
Investigational
Withdrawn
Matched Description: … [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond. …
Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Iupac: … (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol …
Matched Description: … is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 ... [L47036,L47057,L4274,L4278] Globally, it is estimated that approximately 35 to 50 percent of Fabry patients …
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers...
Approved
Investigational
Matched Iupac: … 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine …
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic...
Approved
Investigational
Matched Iupac: … 4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}-2- …
Matched Description: … prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846]. ... In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant …
Matched Categories: … MATE 2 Inhibitors …
Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … (TROP-2) antibody with the topoisomerase I inhibitor SN-38. ... such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2
Matched Categories: … Trop-2-Directed Monoclonal Antibodies …
A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Approved
Investigational
Withdrawn
Matched Iupac: … 1-carbamimidamido-N-(2-phenylethyl)methanimidamide …
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials....
Approved
Investigational
Matched Description: … FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Iupac: … 5-({4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl)methoxy]phenyl}methyl)-1,3-thiazolidine …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other...
Approved
Investigational
Matched Iupac: … (4R,7S,10S,13R,16S,19R,22R)-13-benzyl-22-[(2S)-5-[(diaminomethylidene)amino]-2-acetamidopentanamido]- …
Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Approved
Matched Iupac: … (1S,2R,3aS,3bS,5S,9aS,9bR,10S,11aS)-9b-chloro-5-fluoro-10-hydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl …
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Approved
Investigational
Matched Iupac: … N-{2-[(8S)-1H,2H,6H,7H,8H-indeno[5,4-b]furan-8-yl]ethyl}propanamide …
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Description: … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes …
Matched Categories: … Sodium-Glucose Transporter 2 Inhibitors ... Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors …
A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Approved
Matched Iupac: … methylbis(propan-2-yl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium …
Matched Salts cas: … 50-34-0 …
Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.
Approved
Matched Iupac: … 6,9-bis(2-ethoxyethyl)-3,12-dioxa-6,9-diphosphatetradecane …
Matched Description: … It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. …
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full...
Approved
Investigational
Matched Iupac: … 5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaene …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
Approved
Matched Iupac: … methyloxan-3-yl]oxy}-4-hydroxy-2-methyloxan-3-yl]oxy}-3-hydroxy-2-methyloxan-4-yl acetate ... 11a-dimethyl-1-(5-oxo-2,5-dihydrofuran-3-yl)-hexadecahydro-1H-cyclopenta[a]phenanthren-7-yl]oxy}-4-hydroxy-2- …
Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing symptoms such as difficulty breathing.[A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can...
Approved
Investigational
Matched Iupac: … [2-(acetyloxy)propyl]trimethylazanium …
Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.
Approved
Matched Iupac: … dimagnesium(2+) ion {[dioxido({[oxido(oxo)silyl]oxy})silyl]oxy}silanoylolate …
Matched Salts cas: … 39365-87-2
Matched Mixtures name: … แม๊ก 2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase...
Approved
Investigational
Matched Iupac: … 2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-cyano-3,4-dihydroxyoxolan ... -2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate …
Matched Description: … Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease ... Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for ... A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2
Matched Categories: … Heterocyclic Compounds, 2-Ring ... SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor …
Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading...
Approved
Matched Iupac: … (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid …
Matched Description: … Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition …
Matched Categories: … Adrenergic alpha-2 Receptor Agonists ... Central alpha-2 Adrenergic Agonist …
Displaying drugs 576 - 600 of 11929 in total